Mielóma multiplex: vizsgálatok itt: Kína
204 trials · From ClinicalTrials.gov, checked 2026. november 17.. Ask the study team whether a trial fits you.
- No phaseNot yet taking people in KínaAllogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 18
- Run by
- RenJi Hospital
See details and how to joinNCT06594211 - 3. fázisTaking peopleComparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
- Where
- Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing, Taizhou, Wenzhou
- Életkor
- 18 év to 75 év
- People
- 99
- Run by
- The Affiliated People's Hospital of Ningbo University
See details and how to joinNCT06520176 - No phaseTaking peopleSafety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
- Where
- Kunming
- Életkor
- 18 év to 75 év
- People
- 10
- Run by
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
See details and how to joinNCT06515262 - 1. fázisNot yet taking people in KínaA Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 90
- Run by
- Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT06500507 - No phaseNot yet taking people in KínaLCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
- Where
- Beijing, Hefei, Nanjing, Zhengzhou
- Életkor
- 18 év and over
- People
- 66
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06472479 - No phaseTaking peoplePrimary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
- Where
- Hangzhou
- Életkor
- 18 év to 70 év
- People
- 210
- Run by
- First Affiliated Hospital of Zhejiang University
See details and how to joinNCT06463717 - Korai 1. fázisTaking peopleStudy of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 10
- Run by
- Shanghai Changzheng Hospital
See details and how to joinNCT06407947 - 1/2. fázisTaking peopleOriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
- Where
- Beijing, Hangzhou, Nanjing, Shanghai, Wuhan
- Életkor
- 18 év to 75 év
- People
- 83
- Run by
- OriCell Therapeutics Co., Ltd.
See details and how to joinNCT06182696 - No phaseNot yet taking people in KínaA Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 260
- Run by
- Peking University People's Hospital
See details and how to joinNCT06369935 - 1/2. fázisTaking peopleA Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 154
- Run by
- Beijing Mabworks Biotech Co., Ltd.
See details and how to joinNCT06232096 - Korai 1. fázisNot yet taking people in KínaTo Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 15
- Run by
- Guangdong Second Provincial General Hospital
See details and how to joinNCT06298266 - No phaseTaking peopleUTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 15
- Run by
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT06279026 - 1/2. fázisTaking peopleMitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
- Where
- Nantong
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- Affiliated Hospital of Nantong University
See details and how to joinNCT06246162 - 1/2. fázisTaking peopleSafety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
- Where
- Xuzhou
- Életkor
- 18 év to 70 év
- People
- 20
- Run by
- Xuzhou Medical University
See details and how to joinNCT06196255 - 2. fázisTaking peopleDVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
- Where
- Tianjin
- Életkor
- 18 év to 70 év
- People
- 40
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06158269 - No phaseTaking peopleCardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
- Where
- Jinan
- Életkor
- 18 év to 70 év
- People
- 50
- Run by
- Qilu Hospital of Shandong University
See details and how to joinNCT06039735 - 1/2. fázisTaking peopleSafety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma
- Where
- Xuzhou
- Életkor
- 18 év to 70 év
- People
- 20
- Run by
- Xuzhou Medical University
See details and how to joinNCT06132711 - Korai 1. fázisTaking peopleTo Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 18
- Run by
- Hrain Biotechnology Co., Ltd.
See details and how to joinNCT06045091 - No phaseTaking peopleThe China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 10 000
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT05965115 - No phaseTaking peopleHelical Tomotherapy in Multiple Myeloma
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 58
- Run by
- Fuling Zhou
See details and how to joinNCT05970198 - 1/2. fázisTaking peopleA Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 92
- Run by
- Shanghai AbelZeta Ltd.
See details and how to joinNCT05521802 - 2. fázisTaking peopleHuman BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
- Where
- Shanghai, Wenzhou
- Életkor
- 18 év to 75 év
- People
- 100
- Run by
- Hrain Biotechnology Co., Ltd.
See details and how to joinNCT05594797 - Korai 1. fázisTaking peopleAPRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 36
- Run by
- Zhejiang University
See details and how to joinNCT04657861 - 1. fázisNot yet taking people in KínaA Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
- Where
- Changzhou, Hefei, Nanjing
- Életkor
- 18 év to 70 év
- People
- 20
- Run by
- Nanjing IASO Biotechnology Co., Ltd.
See details and how to joinNCT05181501 - Korai 1. fázisTaking peopleCD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
- Where
- Hangzhou
- People
- 108
- Run by
- Zhejiang University
See details and how to joinNCT04662294